

ISSUE @ A GLANCE



Frontiers in cardiovascular prevention
T.F. Lüscher

329

CardioPulse

James T Willerson MD
M. Nicholls

333

The anti-statin lobby strikes again: time to set the record straight
F. Schiele and S.D. Kristensen

335

Why do the media report negative news about statins?
B.G. Nordestgaard

337

Cardiac screening in Nepal

M. Pazdernik, A. Gabrlikova, R. Tereza, N. Tereza, H. Maria, K. Petr, R. Marketa, U. Hasam, G. Julia, L. Shankar, and T. Kaushal

339

Ride to Barcelona

H. Rickli, P.K. Haager, P. Gnehm, and M. Wilhelm

341

CURRENT OPINION


Clinical update

The Year in Cardiology 2017: Prevention

B.G. Nordestgaard, F. Cosentino, U. Landmesser, and U. Laufs

345

FAST TRACK BASIC SCIENCE



Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
J.C. Hopewell, R. Malik, E. Valdés-Márquez, B.B. Worrall, and R. Collins, METASTROKE Collaboration of the ISGC

354

Editorial

How to use Mendelian randomization to anticipate the results of randomized trials

B.A. Ference

360

FAST TRACK CLINICAL RESEARCH

Heart failure/cardiomyopathy

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME[®] trial

D. Fitchett, J. Butler, P. van de Borne, B. Zinman, J.M. Lachin, C. Wanner, H.J. Woerle, S. Hantel, J.T. George, O.E. Johansen, and S.E. Inzucchi, on behalf of the EMPA-REG OUTCOME[®] trial investigators

363

Editorial


Empagliflozin across the stages of diabetic heart disease

F. Paneni

371

CLINICAL RESEARCH

Coronary artery disease



No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
P.D. Harvey, M.N. Sabbagh, J.E. Harrison, H.N. Ginsberg, M.J. Chapman, G. Manvelian, A. Moryusef, J. Mandel, and M. Farnier

374

Editorial

So low... so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors

B. Gencer and F. Mach

382

Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals

B.K. Lauridsen, S. Stender, T.S. Kristensen, K.F. Kofoed, L. Køber, B.G. Nordestgaard, and A. Tybjaerg-Hansen

385

Editorial

Is a fatty liver (always or ever) bad for the heart?

C.A. Parisinos and A.D. Hingorani

394

Obesity and metabolic syndrome

Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis

C. Lassale, I. Tzoulaki, K.G.M. Moons, M. Sweeting, J. Boer, L. Johnson, J.M. Huerta, C. Agnoli, H. Freisling, E. Weiderpass, P. Wennberg, D.L. van der A, L. Arriola, V. Benetou, H. Boeing, F. Bonnet, S.M. Colorado-Yohar, G. Engström, A.K. Eriksen, P. Ferrari, S. Grioni, M. Johansson, R. Kaaks, M. Katsoulis, V. Katzke, T.J. Key, G. Matullo, O. Melander, E. Molina-Portillo, C. Moreno-Iribas, M. Norberg, K. Overvad, S. Panico, J.R. Quirós, C. Saieva, G. Skeie, A. Steffen, M. Stepien, A. Tjønneland, A. Trichopoulou, R. Tumino, Y.T. van der Schouw, W.M.M. Verschuren, C. Langenberg, E. Di Angelantonio, E. Riboli, N.J. Wareham, J. Danesh, and A.S. Butterworth

397

Editorial

Obesity and prognosis: Time to forget about metabolically healthy obesity

X. Garcia-Moll

407

CARDIOVASCULAR FLASHLIGHTS

- The grandparent and the grandchild separated by 50 years sharing the left ventricular outflow tract
O. Cuevas, A. Weber, F. Maisano, and C.A. Mestres 410
- Unusual presentation of a left atrial tumour prolapsing beyond the aortic valve
S. Shimada, J.A. Copeland, M.V. DeCaro, and J.W.C. Entwistle III 411

LIST OF REVIEWERS

- List of Reviewers 2017 412



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>



www.eurheartj.org